Neos wins FDA okay for its ADHD drug

January 28, 2016 5:55 PM

27 0

Neos wins FDA okay for its ADHD drug

Neos Therapeutics (NASDAQ:NEOS) soared in morning trading after the company’s drug to treat a common type of childhood behavioral disorder was approved by the U.S. Food and Drug Administration.

The drug, Adzenys XR-ODT, is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged six and older, the Texas-based company said in a statement on Thursday.

Also read: U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

Read more

To category page